Click to watch the live stream and join the conversation. #PhRMA16

0 SHARES

0

0

0

1

0 SHARES

0

0

0

1

Fighting Arthritis

Nearly 100 Medicines Are in Development for One of the Most Common Chronic Health Problems in the U.S.

Arthritis is part of a group of related musculoskeletal diseases consisting of more than 100 different conditions.



Arthritis is the most common cause of disability, and is not just a disease of old age. About 40 percent of people with arthritis are under the age of 65, including approximately 294,000 children. The CDC projects prevalence of musculoskeletal diseases could increase to 67 million by 2030 if current trends continue. 

The CDC also estimates that musculoskeletal diseases cost the American economy $128 billion annually in direct medical costs and indirect costs such as lost wages and productivity. Biopharmaceutical research companies are currently developing 92 medicines to help the millions of Americans affected by arthritis. 

52+ Million Afflicted

More than 100 different kinds of musculoskeletal diseases, including arthritis, affect more than 52 million Americans each year.

Learn More

The Future of Musculoskeletal Diseases

By 2030, 67 million are projected to be diagnosed with musculoskeletal diseases. However, over the past two decades, our understanding of the value of new treatments has evolved yielding dramatic patient benefits. Because of the incremental and evolving nature of clinical research, it is important to recognize that the full value of a treatment is not completely understood at the time of initial market approval. Policies that are sensitive to the way value emerges over time will help incentivize future innovation.

Learn More About Innovative Treatments for Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis Affects 300,000 Children

35%



Chance of Complete Clinical Remission

A 2010 study found patients treated with combination therapy consisting of a new biologic and an older medicine had a 35% chance of complete clinical remission over the course of five years, compared with 14% for those taking only the older medicine—more than doubling remission rates for patients.

Learn More

Juvenile Arthritis  

Approximately 294,000 children are affected by juvenile arthritis and rheumatologic conditions, making it one of the most common childhood diseases in the United States. Juvenile arthritis refers to any form of arthritis or related condition that develops in children or teenagers who are younger than age 18.

1 Million

hospitalizations each year are caused by arthritis and related conditions. The disease causes an additional 44 million outpatient visits per year.

Learn More

Medicines in the Pipeline

America’s biopharmaceutical research companies are developing 92 medicines to help the millions of Americans affected by arthritis. These medicines in development include 55 for rheumatoid arthritis (RA), 15 for musculoskeletal pain, 10 for osteoarthritis and 7 for psoriatic arthritis. Today, modern biologic disease-modifying anti-rheumatic drugs go beyond just treating symptoms to target sources of inflammation, improve physical function, prevent joint damage, and enable disease remission. Read the latest report on medicines in development for RA and other challenging autoimmune diseases, and learn about other treatments currently in development here:

Learn More

Related Medicines

Back

Resources

View additional resources to learn more about medicines currently in development to treat and prevent arthritis and musculoskeletal diseases: